Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications

Alzheimer’s disease (AD) is characterized by a progressive phenotypic downregulation of markers within cholinergic basal forebrain (CBF) neurons, frank CBF cell loss and reduced cortical choline acetyltransferase activity associated with cognitive decline. Delaying CBF neurodegeneration or minimizing its consequences is the mechanism of action for most currently available drug treatments for cognitive dysfunction in AD. Growing evidence suggests that imbalances in the expression of NGF, its precursor proNGF and the high (TrkA) and low (p75NTR) affinity NGF receptors are crucial factors underlying CBF dysfunction in AD. Drugs that maintain a homeostatic balance between TrkA and p75NTR may slow the onset of AD. A NGF gene therapy trial reduced cognitive decline and stimulated cholinergic fiber growth in humans with mild AD. Drugs treating the multiple pathologies and clinical symptoms in AD (e.g., M1 cholinoceptor and/or galaninergic drugs) should be considered for a more comprehensive treatment approach for cholinergic dysfunction.

[1]  F. Gage,et al.  Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. , 1996, Gene therapy.

[2]  J. Wuu,et al.  Reduction of cortical TrkA but not p75NTR protein in early‐stage Alzheimer's disease , 2004, Annals of neurology.

[3]  E. Coulson,et al.  The p75 neurotrophin receptor. , 2008, The international journal of biochemistry & cell biology.

[4]  S. Wisniewski,et al.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment , 2002, Annals of neurology.

[5]  Richard Weindruch,et al.  A TrkA-to-p75NTR molecular switch activates amyloid beta-peptide generation during aging. , 2005, The Biochemical journal.

[6]  C. Geula,et al.  Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability , 1993, Annals of neurology.

[7]  J. Jhamandas,et al.  Galanin attenuates β-amyloid (Aβ) toxicity in rat cholinergic basal forebrain neurons , 2006, Neurobiology of Disease.

[8]  S. Iwata,et al.  Allosteric Activation of L-Lactate Dehydrogenase Analyzed by Hybrid Enzymes with Effector-sensitive and -insensitive Subunits* , 1996, The Journal of Biological Chemistry.

[9]  F. Gage,et al.  Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain , 1991, Annals of neurology.

[10]  T. Kameyama,et al.  Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats. , 1994, Gerontology.

[11]  D. Stein,et al.  Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death , 2007, Proceedings of the National Academy of Sciences.

[12]  M. Barbacid.  Structural and Functional Properties of the TRK Family of Neurotrophin Receptors , 1995, Annals of the New York Academy of Sciences.

[13]  F. LaFerla,et al.  M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice , 2006, Neuron.

[14]  Tao Yang,et al.  Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer's disease mechanisms. , 2007, Current Alzheimer research.

[15]  A. Fisher.  M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer’s Disease – The Pivotal Role of Brain M1 Receptors , 2008, Neurodegenerative Diseases.

[16]  K. Davis,et al.  Cholinergic markers in elderly patients with early signs of Alzheimer disease. , 1999, JAMA.

[17]  M. Mesulam,et al.  Cholinergic nucleus basalis tauopathy emerges early in the aging‐MCI‐AD continuum , 2004, Annals of neurology.

[18]  K. Burgess,et al.  Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA , 2004, The Journal of Neuroscience.

[19]  E. Shooter,et al.  Binding of nerve growth factor to its p75 receptor in stressed cells induces selective IκB‐β degradation and NF‐κB nuclear translocation , 2001 .

[20]  G. V. Van Hoesen,et al.  Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. , 1984, Science.

[21]  Mary Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[22]  R. Stephens,et al.  The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth , 1999, Oncogene.

[23]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[24]  Y. Agid,et al.  Choline acetyltransferase activity and [ 3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions , 1990, Neuroscience.

[25]  R. Quirion,et al.  Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies , 2002, Progress in Neurobiology.

[26]  A. Futerman,et al.  Ceramide Signaling Downstream of the p75 Neurotrophin Receptor Mediates the Effects of Nerve Growth Factor on Outgrowth of Cultured Hippocampal Neurons , 1999, The Journal of Neuroscience.

[27]  H. Hinterhuber,et al.  Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias , 2005, Dementia and Geriatric Cognitive Disorders.

[28]  S. DeKosky,et al.  Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. , 2007, Archives of neurology.

[29]  C. Pozniak,et al.  The p75 Neurotrophin Receptor Mediates Neuronal Apoptosis and Is Essential for Naturally Occurring Sympathetic Neuron Death , 1998, The Journal of cell biology.

[30]  Steven G Potkin,et al.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.

[31]  E. Mufson,et al.  The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. , 2005, Journal of neuropathology and experimental neurology.

[32]  R. Nitsch,et al.  Molecules Involved in Reactive Sprouting in the Hippocampus , 2001, Reviews in the neurosciences.

[33]  F. Schmitt,et al.  Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[34]  S. Arnold,et al.  A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? , 2005, Trends in pharmacological sciences.

[35]  V. Chan‐Palay.  Galanin hyperinnervates surviving neurons of the human basal nucleus of meynert in dementias of alzheimer's and parkinson's disease: A hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia , 1988, The Journal of comparative neurology.

[36]  L. Matrisian,et al.  Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications , 1999, Annals of the New York Academy of Sciences.

[37]  Fei Liu,et al.  Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation , 2005, The European journal of neuroscience.

[38]  D. H. Lee,et al.  Increased Alpha 7 Nicotinic Acetylcholine Receptor Protein Levels in Alzheimer’s Disease Patients , 2005, Dementia and Geriatric Cognitive Disorders.

[39]  A. Fisher,et al.  AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. , 2002, Journal of molecular neuroscience : MN.

[40]  M. Chao,et al.  Competitive Signaling Between TrkA and p75 Nerve Growth Factor Receptors Determines Cell Survival , 1998, The Journal of Neuroscience.

[41]  M. Schwab,et al.  NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? , 1983, Brain research.

[42]  M. Tcherpakov,et al.  Nerve Growth Factor-induced p75-mediated Death of Cultured Hippocampal Neurons Is Age-dependent and Transduced through Ceramide Generated by Neutral Sphingomyelinase* , 2002, The Journal of Biological Chemistry.

[43]  C. Morris,et al.  Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[44]  J. Wuu,et al.  Increased proNGF Levels in Subjects with Mild Cognitive Impairment and Mild Alzheimer Disease , 2004, Journal of neuropathology and experimental neurology.

[45]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[46]  J. Schneider,et al.  Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions , 2005, Neurology.

[47]  J. Trojanowski,et al.  Expression profile of transcripts in Alzheimer's disease tangle‐bearing CA1 neurons , 2000, Annals of neurology.

[48]  W. Benzing,et al.  Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer's disease and Down's syndrome. , 1993, Dementia.

[49]  K. Kimpinski,et al.  Neurite growth promotion by nerve growth factor and insulin‐like growth factor‐1 in cultured adult sensory neurons: Role of phosphoinositide 3‐kinase and mitogen activated protein kinase , 2001, Journal of neuroscience research.

[50]  F. Hefti,et al.  Comparison of nerve growth factor's effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro , 1988, Journal of neuroscience research.

[51]  S. Wisniewski,et al.  Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[52]  E. Masliah,et al.  NGF-mediated synaptic sprouting in the cerebral cortex of lesioned primate brain , 1995, Brain Research.

[53]  C. Shatz,et al.  A Novel P75ntr Signaling Pathway Promotes Survival, Not Death, of Immunopurified Neocortical Subplate Neurons , 2022 .

[54]  David R Kaplan,et al.  Neurotrophin signal transduction in the nervous system , 2000, Current Opinion in Neurobiology.

[55]  Barbara L. Hempstead,et al.  Regulation of Cell Survival by Secreted Proneurotrophins , 2001, Science.

[56]  V. Caputo,et al.  Insights into the interaction of sortilin with proneurotrophins: A computational approach , 2008, Neuropeptides.

[57]  K. Davis,et al.  Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits , 1995, Journal of neurochemistry.

[58]  I. Grundke‐Iqbal,et al.  Phosphothreonine-212 of Alzheimer Abnormally Hyperphosphorylated Tau is a Preferred Substrate of Protein Phosphatase-1 , 2005, Neurochemical Research.

[59]  L. Klesse,et al.  Trks: Signal transduction and intracellular pathways , 1999, Microscopy research and technique.

[60]  A. Patapoutian,et al.  Trk receptors: mediators of neurotrophin action , 2001, Current Opinion in Neurobiology.

[61]  D A Bennett,et al.  Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease , 1999, The Journal of comparative neurology.

[62]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[63]  Serge Gauthier,et al.  Advances in the pharmacotherapy of Alzheimer's disease. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[64]  S. Leurgans,et al.  Loss of basal forebrain P75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease , 2002, The Journal of comparative neurology.

[65]  T. Powell,et al.  Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase , 1983, Brain Research.

[66]  E. Mufson,et al.  Galanin Hyperinnervation Upregulates Choline Acetyltransferase Expression in Cholinergic Basal Forebrain Neurons in Alzheimer’s Disease , 2008, Neurodegenerative Diseases.

[67]  P. Cohen,et al.  Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases , 1991, Nature.

[68]  G. Buzsáki,et al.  Survival, growth and function of damaged cholinergic neurons. , 1989, EXS.

[69]  F. Hefti,et al.  Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[70]  A. Wimo.  Clinical and economic outcomes – friend or foe? , 2007, International Psychogeriatrics.

[71]  D. Katzenstein,et al.  A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection , 2000, Neurology.

[72]  R. Heumann,et al.  Nerve growth factor stimulates MAPK via the low affinity receptor p75LNTR , 1999 .

[73]  P. Cohen,et al.  Activation of the MAP kinase pathway by the protein kinase raf , 1992, Cell.

[74]  A. Nappi,et al.  Alzheimer ' s Disease : Cell-Specific Pathology Isolates the Hippocampal Formation , 2022 .

[75]  R. Doody,et al.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study , 2000, European Neuropsychopharmacology.

[76]  L. Eiden.  The Cholinergic Gene Locus , 1998, Journal of neurochemistry.

[77]  Xin Yu,et al.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. , 2003, The American journal of psychiatry.

[78]  R. Crowther,et al.  Cloning and sequencing of the cDNA encoding an isoform of microtubule‐associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. , 1989, The EMBO journal.

[79]  E. Mufson,et al.  Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease. , 2006, Progress in brain research.

[80]  M. D'Andrea,et al.  Intracellular accumulation of β-amyloid1–42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer’s disease , 2002, Neuroscience.

[81]  Philippe P Roux,et al.  The p75 Neurotrophin Receptor (p75NTR) Alters Tumor Necrosis Factor-mediated NF-κB Activity under Physiological Conditions, but Direct p75NTR-mediated NF-κB Activation Requires Cell Stress* , 1999, The Journal of Biological Chemistry.

[82]  A. Blesch.  Delivery of neurotrophic factors to neuronal targets: toward gene therapy in the CNS. , 2000, Drug news & perspectives.

[83]  S. Lorenzl,et al.  Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases , 2003, Journal of the Neurological Sciences.

[84]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[85]  S. Lad,et al.  Distinction between differentiation, cell cycle, and apoptosis signals in PC12 cells by the nerve growth factor mutant Δ9/13, which is selective for the p75 neurotrophin receptor , 2001, Journal of neuroscience research.

[86]  S. Lorenzl,et al.  Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia , 2008, International Psychogeriatrics.

[87]  C. Humpel,et al.  Nerve growth factor and cholinergic CNS neurons studied in organotypic brain slices. Implication in Alzheimer's disease? , 2002, Journal of neural transmission. Supplementum.

[88]  E. Mufson,et al.  Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate , 1996, Brain Research.

[89]  R. Bartus,et al.  On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic Hypothesis , 2000, Experimental Neurology.

[90]  E. Mufson,et al.  Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. , 2003, Current drug targets. CNS and neurological disorders.

[91]  J. Lah,et al.  Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel γ-secretase substrates , 2006, Molecular Neurodegeneration.

[92]  Philippe P Roux,et al.  The p75 Neurotrophin Receptor Activates Akt (Protein Kinase B) through a Phosphatidylinositol 3-Kinase-dependent Pathway* , 2001, The Journal of Biological Chemistry.

[93]  D. Small,et al.  The β‐amyloid protein of Alzheimer’s disease binds to membrane lipids but does not bind to the α7 nicotinic acetylcholine receptor , 2007 .

[94]  S. DeKosky,et al.  Galanin Fiber Hypertrophy within the Cholinergic Nucleus Basalis during the Progression of Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[95]  G. Lynch,et al.  Synaptic rearrangement in the dentate gyrus: histochemical evidence of adjustments after lesions in immature and adult rats. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[96]  A. Levey,et al.  Coordinate Expression of the Vesicular Acetylcholine Transporter and Choline Acetyltransferase Following Septohippocampal Pathway Lesions , 1998, Journal of neurochemistry.

[97]  F. Gage,et al.  Gene therapy in the CNS: intracerebral grafting of genetically modified cells. , 1990, Progress in brain research.

[98]  E. Mufson,et al.  Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. , 2007, Current Alzheimer research.

[99]  S. Apfel,et al.  Neurotrophic Factor Therapy – Prospects and Problems , 2001, Clinical chemistry and laboratory medicine.

[100]  J. Peyrat,et al.  Nerve Growth Factor Stimulates Proliferation and Survival of Human Breast Cancer Cells through Two Distinct Signaling Pathways* , 2001, The Journal of Biological Chemistry.

[101]  M. Jönhagen.  Nerve Growth Factor Treatment in Dementia , 2000, Alzheimer disease and associated disorders.

[102]  G. V. Van Hoesen,et al.  Reinnervation of the hippocampal perforant pathway zone in Alzheimer's disease , 1987, Annals of neurology.

[103]  D. Kaplan,et al.  Depolarization and Neurotrophins Converge on the Phosphatidylinositol 3-Kinase–Akt Pathway to Synergistically Regulate Neuronal Survival , 1999, The Journal of cell biology.

[104]  M. Tuszynski,et al.  Ex vivo gene therapy for Alzheimer's disease and spinal cord injury. , 1995, Clinical neuroscience.

[105]  E. Mufson,et al.  Shift in the ratio of three‐repeat tau and four‐repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease , 2006, Journal of neurochemistry.

[106]  E. Perry,et al.  Cholinesterase inhibitors reduce cortical Aβ in dementia with Lewy bodies , 2007, Neurology.

[107]  P J Whitehouse,et al.  Pharmacotherapy for Alzheimer's disease. , 1994, Clinics in geriatric medicine.

[108]  H. Hatanaka,et al.  Nerve growth factor promotes survival of cultured magnocellular cholinergic neurons from nucleus basalis of Meynert in postnatal rats , 1988, Neuroscience Letters.

[109]  E. Giacobini.  Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[110]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[111]  J. Nyengaard,et al.  Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury , 2007, Nature Neuroscience.

[112]  J. Jhamandas,et al.  Novel excitatory actions of galanin on rat cholinergic basal forebrain neurons: implications for its role in Alzheimer's disease. , 2002, Journal of neurophysiology.

[113]  V. Mamidipudi,et al.  Dual role for p75NTR signaling in survival and cell death: Can intracellular mediators provide an explanation? , 2002, Journal of neuroscience research.

[114]  E. Mufson,et al.  Galanin plasticity in the cholinergic basal forebrain in Alzheimer’s disease and transgenic mice , 2005, Neuropeptides.

[115]  S. Ginsberg,et al.  Ultrastructural analysis of the progression of neurodegeneration in the septum following fimbria–fornix transection , 1998, Neuroscience.

[116]  E. Mufson,et al.  m2 muscarinic acetylcholine receptor‐immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: Relationship with cholinergic and galaninergic perikarya , 1998, The Journal of comparative neurology.

[117]  M. Andjelkovic,et al.  Nerve growth factor promotes activation of the alpha, beta and gamma isoforms of protein kinase B in PC12 pheochromocytoma cells. , 1998, European journal of biochemistry.

[118]  E. Perry,et al.  CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE , 1978, Neuropathology and applied neurobiology.

[119]  Barbara L. Hempstead,et al.  Sortilin is essential for proNGF-induced neuronal cell death , 2004, Nature.

[120]  E Schwarz,et al.  The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. , 2001, European journal of biochemistry.

[121]  T. Hökfelt,et al.  Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[122]  D. Kaplan,et al.  Neurobiology: A move to sort life from death , 2004, Nature.

[123]  Steven T. DeKosky,et al.  Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction , 2003, Journal of Chemical Neuroanatomy.

[124]  D. Bennett,et al.  Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment , 2001, Annals of neurology.

[125]  S. DeKosky,et al.  Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders , 2003, Science.

[126]  E. Mufson,et al.  Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain , 1989, Experimental Neurology.

[127]  R. Dobrowsky,et al.  Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. , 1994, Science.

[128]  J. Trojanowski,et al.  Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[129]  W. Friedman.  Neurotrophins Induce Death of Hippocampal Neurons via the p75 Receptor , 2000, The Journal of Neuroscience.

[130]  W. Rutter,et al.  Processing of the native nerve growth factor precursor to form biologically active nerve growth factor. , 1988, The Journal of biological chemistry.

[131]  J. Kim,et al.  Activation of Rac GTPase by p75 Is Necessary for c-jun N-Terminal Kinase-Mediated Apoptosis , 2002, The Journal of Neuroscience.

[132]  A. Davies,et al.  p75-Mediated NF-κB Activation Enhances the Survival Response of Developing Sensory Neurons to Nerve Growth Factor , 1999, Molecular and Cellular Neuroscience.

[133]  E. Nishida,et al.  Suppression of Nerve Growth Factor-induced Neuronal Differentiation of PC12 Cells , 1996, The Journal of Biological Chemistry.

[134]  S. Skaper.  The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. , 2008, CNS & neurological disorders drug targets.

[135]  F. Gage,et al.  NGF induction of NGF receptor gene expression and cholinergic neuronal hypertrophy within the basal forebrain of the adult rat , 1989, Neuron.

[136]  G. Barrett.  The p75 neurotrophin receptor and neuronal apoptosis , 2000, Progress in Neurobiology.

[137]  A. Nordberg.  Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[138]  Philippe P Roux,et al.  Neurotrophin signaling through the p75 neurotrophin receptor , 2002, Progress in Neurobiology.

[139]  K. Teng,et al.  Neurotrophins and their receptors: signaling trios in complex biological systems , 2003, Cellular and Molecular Life Sciences CMLS.

[140]  D. German,et al.  Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type , 1985, Neurology.

[141]  Guanhua Yu,et al.  The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor , 2004, Journal of neurochemistry.

[142]  N. Kerr,et al.  Galanin – 25 years with a multitalented neuropeptide , 2008, Cellular and Molecular Life Sciences.

[143]  J. Frade,et al.  Unscheduled re-entry into the cell cycle induced by NGF precedes cell death in nascent retinal neurones. , 2000, Journal of cell science.

[144]  B. Sykes,et al.  Growth factor receptors: structure, mechanism, and drug discovery. , 1997, Biopolymers.

[145]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[146]  J. Wuu,et al.  Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease , 2006, Journal of neurochemistry.

[147]  C. Altar,et al.  Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[148]  A. Fisher.  M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update. , 2007, Current Alzheimer research.

[149]  M. Fainzilber,et al.  Multi‐tasking by the p75 neurotrophin receptor: sortilin things out? , 2004, EMBO reports.

[150]  B. Michalski,et al.  The Precursor Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's Disease , 2001, Molecular and Cellular Neuroscience.

[151]  E. Mufson,et al.  Galanin in Alzheimer disease. , 2003, Molecular interventions.

[152]  J. Brion,et al.  Expression of tau mRNA and soluble tau isoforms in affected and non‐affected brain areas in Alzheimer's disease , 2004, FEBS letters.

[153]  N. Cutler,et al.  Recent Developments in the Drug Treatment of Alzheimer’s Disease , 1999, Drugs & aging.

[154]  S. Tanada,et al.  Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study , 2000, Annals of neurology.

[155]  S. Apfel.  Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? , 2002, International review of neurobiology.

[156]  A. Lees,et al.  Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions , 2004, Acta Neuropathologica.

[157]  E. Mufson,et al.  Nerve Growth Factor Systems in Alzheimer’s Disease , 1999 .

[158]  S. Leurgans,et al.  Cortical biochemistry in MCI and Alzheimer disease , 2007, Neurology.

[159]  J. Coyle,et al.  Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.

[160]  E. Cochran,et al.  Down‐regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease , 2001, The Journal of comparative neurology.

[161]  H. Gao,et al.  Neurotrophins and Alzheimer's disease: beyond the cholinergic neurons. , 1996, Life sciences.

[162]  A. Cuello,et al.  Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[163]  V. Rajmohan,et al.  Neurobiology of Alzheimer's disease , 2009, Indian journal of psychiatry.

[164]  D. Christensen.  Alzheimer's Disease: Progress in the Development of Anti-amyloid Disease-Modifying Therapies , 2007, CNS Spectrums.

[165]  D. Amaral,et al.  Nerve growth factor infusion in the primate brain reduces lesion- induced cholinergic neuronal degeneration , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[166]  P. Dijkhuizen,et al.  Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease , 1996, Neuroscience.

[167]  M. Raskind,et al.  Nerve growth factor induces galanin gene expression in the rat basal forebrain: Implications for the treatment of cholinergic dysfunction , 1997, The Journal of comparative neurology.

[168]  A. Nordberg,et al.  Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. , 1999, Brain research. Molecular brain research.

[169]  Barbara L. Hempstead,et al.  ProBDNF Induces Neuronal Apoptosis via Activation of a Receptor Complex of p75NTR and Sortilin , 2005, The Journal of Neuroscience.

[170]  M. Tuszynski,et al.  Reversible schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor , 1997, Annals of neurology.

[171]  J. Price,et al.  Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.

[172]  Claudia Linker,et al.  Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme , 1996, Neuron.

[173]  F. Hefti,et al.  Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases , 1989, Neurobiology of Aging.

[174]  E. Cochran,et al.  Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease , 2000, The Journal of comparative neurology.

[175]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[176]  J. Shine,et al.  The Second Galanin Receptor GalR2 Plays a Key Role in Neurite Outgrowth from Adult Sensory Neurons , 2003, The Journal of Neuroscience.

[177]  J. Bishop,et al.  Nerve growth factor rapidly stimulates tyrosine phosphorylation of phospholipase C-gamma 1 by a kinase activity associated with the product of the trk protooncogene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[178]  J. Crawley.  Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease. , 2008, Cellular and molecular life sciences : CMLS.

[179]  F. Gage,et al.  Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[180]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[181]  E. Perry,et al.  Alzheimer's disease is associated with a selective increase in α7 nicotinic acetylcholine receptor immunoreactivity in astrocytes , 2003, Glia.

[182]  K. Någren,et al.  Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[183]  P. A. Peterson,et al.  β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity , 2000, The Journal of Biological Chemistry.

[184]  W C Greene,et al.  NF-κB Signaling Promotes Both Cell Survival and Neurite Process Formation in Nerve Growth Factor-Stimulated PC12 Cells , 2000, The Journal of Neuroscience.

[185]  E. Mufson,et al.  Gene Expression Profiles of Cholinergic Nucleus Basalis Neurons in Alzheimer's Disease , 2002, Neurochemical Research.

[186]  P. Casaccia‐Bonnefil,et al.  Nerve Growth Factor Activation of Nuclear Factor κB through Its p75 Receptor Is an Anti-apoptotic Signal in RN22 Schwannoma Cells* , 2000, The Journal of Biological Chemistry.

[187]  A. Shetter,et al.  Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations , 1992 .

[188]  C. Gotti,et al.  Human neuronal nicotinic receptors , 1997, Progress in Neurobiology.

[189]  S. R. Datta,et al.  Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. , 1999, Science.

[190]  M. Sofroniew,et al.  Nerve growth factor signaling, neuroprotection, and neural repair. , 2001, Annual review of neuroscience.

[191]  T. Pawson,et al.  Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF responses , 1994, Neuron.

[192]  L. Greene,et al.  A function–structure model for NGF‐activated TRK , 1998, The EMBO journal.

[193]  Andrew J Saykin,et al.  Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. , 2004, Brain : a journal of neurology.

[194]  S. Grewal,et al.  Extracellular-signal-regulated kinase signalling in neurons , 1999, Current Opinion in Neurobiology.

[195]  R. A. Crowther,et al.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease , 1989, Neuron.

[196]  B. Hyman,et al.  Transcriptional and conformational changes of the tau molecule in Alzheimer's disease. , 2005, Biochimica et biophysica acta.

[197]  J. Rinne,et al.  Neuronal size and density in the nucleus basalis of Meynert in Alzheimer's disease , 1987, Journal of the Neurological Sciences.